GTx (GTXI)

SUMMARY

BULLS

BEARS

DATA CENTRAL

Day
52 Wk

GTx posts positive data for an unmet cancer need

FierceBiotech Jun 12

One of a new class of drugs being advanced by GTx delivered positive data in a mid-stage trial to combat muscle wasting in cancer patients--an unmet medical need with no currently approved therapeutics. Memphis-based GTx says that...

GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting

Business Wire Jun 11

GTx, Inc. (Nasdaq: GTXI) today announced results of a Phase II clinical trial evaluating Ostarine™ (MK-2866), an investigational selective androgen receptor modulator (SARM), in patients with cancer induced muscle loss, also known as cancer

GTx Announces Ostarine™ (MK-2866) Clinical Trial Data to be Presented at ENDO 2009

Business Wire Jun 8

GTx, Inc. (NASDAQ: GTXI), today announced that results of the Phase II clinical trial evaluating Ostarine™ (MK-2866) for the treatment of cancer cachexia will be presented at ENDO 2009, The Endocrine Society’s Annual Meeting, being held in

GTx Announces Webcast of Corporate Presentation at Goldman Sachs 30th Annual Global Healthcare Conference

Business Wire Jun 2

GTx, Inc. (NASDAQ: GTXI), announced today that management will participate in the Goldman Sachs 30th Annual Global Healthcare Conference on June 9, 2009. The GTx presentation will begin at 11:55 a.m. Eastern time. A live webcast of the presentation

GTx's Toremifene 80 Mg Increased Bone Mineral Density in Multiple Clinically Relevant Subpopulations of Prostate Cancer Patients on Androgen Deprivation Therapy

Business Wire Jun 1

GTx, Inc. (Nasdaq: GTXI) announced the presentation yesterday of data demonstrating that toremifene 80 mg treatment compared to placebo increased bone mineral density (BMD) in multiple clinically relevant subpopulations of men with prostate cancer on

GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data to be Presented at the Annual Meeting of the American Society of Clinical Oncology

Business Wire May 28

GTx, Inc. (NASDAQ: GTXI) today announced that data from the Phase III clinical trial evaluating toremifene 80 mg for the prevention of fractures in men with prostate cancer on androgen deprivation therapy will be presented at the 2009 Annual Meeting

GTX Corp and Aetrex Worldwide, Inc. Enter Platform Test Agreement to Bring GPS Shoes to Senior Market

Market Wire May 27

LOS ANGELES, CA -- (Marketwire) -- 05/27/09 -- GTX Corp (OTCBB: GTXO), a leader in customizable, patented 2-way GPS Personal Location Services (PLS) solutions, and Aetrex Worldwide, Inc., a global leader in pedorthic footwear and foot orthotics, have

GTX Corp Combines 2-Way GPS, Proximity Alerting and Apple Inc's 3.0 OS Delivering Social Location Awareness at the Touch of a Button

Market Wire May 20

LOS ANGELES, CA -- (Marketwire) -- 05/20/09 -- GTX Corp (OTCBB: GTXO), a leader in customizable, patented 2-way GPS Personal Location Services (PLS) solutions, plans to launch new apps this summer. The Company is expanding its LOCi brand with the

GTx, Inc. Reports First Quarter 2009 Results

Business Wire May 11

GTx, Inc. (NASDAQ: GTXI) today reported financial results for the first quarter of 2009. The net loss for the first quarter was $11.3 million compared with a net loss of $12.7 million for the same period in 2008. At March 31, 2009, GTx had cash, cash

GTx, Inc. Announces First Quarter 2009 Corporate Results Conference Call and Webcast

Business Wire May 4

GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to discuss the Company’s first quarter 2009 corporate results on Monday, May 11 at 9:00 a.m. Eastern. The call and webcast will follow the release of the first

Suggest other news sources for this topic


	Suggest a News Source Topic Top news source/blog that we're missing Why do you recommend this news source? Close Thanks for your suggestion!

The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.

You may also be interested in articles related to GTx (GTXI):

Wanted Companies

[edit] References

Retrieved from "http://www.wikinvest.com/stock/GTx_(GTXI)"

Categories: Pharma & Healthcare | Biotechnology

Worried about pump and dump?

We review changes
for stock spam

» read more

Want to make Wikinvest better?

We need your help,
contribute today

» learn how

Do you write software?

We are recruiting
the best engineers

» view jobs

Like Wikinvest?

Spread the word —
Tell your friends!

» spread the word

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.